Paclitaxel in the multimodality treatment for inflammatory breast carcinoma
Authors:
- Massimo CristofanilliMCMassimo Cristofanilli
- Naoto UenoNUNaoto Ueno
Open Access
Abstract
BACKGROUND Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast carcinoma. Anthracycline‐based regimens represent the standard of treatment for IBC. Reports of significant clinical activity of paclitaxel in metastatic breast carcinoma led the authors to investigate the role of this drug in the management of IBC. METHODS Forty‐four patients with IBC were enrolled between February 1994 and January 1998. The treatment plan consisted of induction chemotherapy (IC), mastectomy, adjuvant chemotherapy, and radiotherapy. Forty‐two patients received IC with four cycles of fluorouracil, doxorubicin, and cyclophosphamide. If the clinical response was less than partial, patients were “crossed over” to paclitaxel before mastectomy. All patients received adjuvant paclitaxel. Patients unresectable after paclitaxel were offered high‐dose chemotherapy with autologous peripheral blood progenitor cell support. RESULTS Thirty‐four patients (81%) achieved an objective clinical remission; 3 patients (7%) achieved a clinical complete remission, 31 (74%) a partial remission. Six patients (14%) achieved pathologic complete remission. Sixteen patients were treated with paclitaxel, 7 of them (44%) were able to undergo mastectomy. Median time to progression (TTP) was 22 months. Median overall survival (OS) was 46 months. Concordance between clinical and pathologic response was documented in only 8 patients (24%). No differences in TTP and OS compared with a historical group of 178 IBC patients treated with anthracycline‐based regimens. CONCLUSIONS Paclitaxel improves tumor resectability in anthracycline‐refractory IBC. The impact of paclitaxel on the prognosis of IBC needs to be better evaluated in future trials using more dose‐intensive schedules of administration. New imaging modalities may contribute to improve assessment of response to IC. Cancer 2001;92:1775–82. © 2001 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast CancerJournal of Clinical Oncology, 1999
- First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)British Journal of Cancer, 1999
- Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinomaCancer, 1999
- Inflammatory breast carcinoma incidence and survivalCancer, 1998
- High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.Journal of Clinical Oncology, 1998
- Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer CenterCancer Chemotherapy and Pharmacology, 1997
- Mammographic patterns of inflammatory breast carcinoma: a retrospective study of 92 casesEuropean Journal of Radiology, 1997
- Combined Modality Treatment of Stage III and Inflammatory Breast CancerSurgical Oncology Clinics of North America, 1995
- Inflammatory breast carcinoma: mammographic findings.Radiology, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958